Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors

Lipton, J.H., Bryden, P., Sidhu, M.K., Huang, H., McGarry, L.J., Lustgarten, S., Mealing, S., Woods, B., Whelan, J. and Hawkins, N. (2015) Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leukemia Research, 39(1), pp. 58-64. (doi:10.1016/j.leukres.2014.10.005) (PMID:25466286)

Full text not currently available from Enlighten.

Abstract

We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.

Item Type:Articles
Additional Information:Research funding for this analysis was provided by ARIAD Pharmaceuticals, Inc.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Hawkins, Professor Neil
Authors: Lipton, J.H., Bryden, P., Sidhu, M.K., Huang, H., McGarry, L.J., Lustgarten, S., Mealing, S., Woods, B., Whelan, J., and Hawkins, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Leukemia Research
Publisher:Elsevier
ISSN:0145-2126
ISSN (Online):0145-2126
Published Online:01 November 2014

University Staff: Request a correction | Enlighten Editors: Update this record